Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Karin,
For clarity, in case it got lost in the shuffle, I was(am) arguing in support of the non-employee directors. Those quotes I included in paranthesis were SS's.
And I expect no response from SS.
petemantx,
I trust you are being facitious with that response?
I may not agree with all "longs", but was raised to question, at times.
My hope has diminished, but I'm still long(holding out some hope).
GL to you, me, and all longs
C'mon man,
IPIX is now awaiting news on it's successfully completed Phase2b psoriasis trial."
Please provide your source that it has "successfully completed Phase2b psoriasis trial", as measured by the outcome measures. Is that what you mean? The last person to cross the finish line at the Boston Marathon has , technically, completed the Marathon(trial).
What say you?
I regard your post as disingenuous if justifaction of your quote(ie, company source, or other high ender in the know) is not provided by you.
"These guys are total lightweights, have little to no experience in biotech, and no connections. They rubber-stamp every decision."
Please justify, with examples, your above noted accusation.
Barry Schechter, M.D., F.A.A.O: "Dr. Schechter has reviewed articles for Cornea, the British Journal of Ophthalmology, and the Journal of the American Academy of Ophthalmology. He has lectured internationally and published on the subjects of treatment of ocular tumors, lens implants and dry eyes. Dr. Schechter has also written a textbook chapter on surgical techniques. Dr. Schechter is involved in clinical research and consults for several ophthalmic pharmaceutical companies. I guess that's no biotech experience by your definition. By your measure, Dr. Stephen Sonis is a light weight as well in OM, correct? If so, why?
Inflamation is associated with many diseases of the eye(s), his addition makes sense to me in that regard.
I expect no response from you.
Zorik Spektor, M.D., F.A.A.P: "Prior to establishing the Center for Pediatric ENT – Head and Neck Surgery in 1995, Dr. Spektor was on the faculty of the University of Connecticut Health Science Center, Hartford Hospital and Newington Children’s Hospital, now known as Connecticut Children’s Hospital. He has lectured and presented extensively in the field of pediatric otolaryngology, and has authored numerous peer-reviewed publications. Dr. Spektor has been a presenter as well as an invited speaker at local, national and international conferences. He continually conducts clinical research studies, which have produced significant advances in the field of otolaryngology and pediatric otolaryngology. During the past decade he has been selected as one of the nation’s top doctors by several independent rating agencies for many consecutive years. Dr. Spektor has served on advisory boards for several medical device and pharmaceutical companies and has been involved in significant advances in the field of otolaryngology and Pediatric Otolaryngology."
Again, no biotech experience?
Again, I expect no response from you.
Mark Tobin:http://printronix.com/about-us/our-team/norm-judd/
I expect no response from you, and must say, I consider you light weight as far as pro's are concerned(and I don''t claim to be a pro- just so you know)
In an effort to convince myself I haven't had the wool pulled over my eyes, I reviewed the qualifications of non-employee company directors(which I heven't done in a while). Not bad actually. From last 10K(sept. 2017).
Also, info on Tobin(only one who is not a physician) and the company he's cfo of, Printronix.
http://printronix.com/about-us/our-team/norm-judd/
Barry Schechter, M.D., F.A.A.O., joined the Board on October 1, 2014 as an independent member. Dr. Schechter has been the Director of Department of Cornea and External Disease at Florida Eye Microsurgical Institute since 2005. Dr. Schechter’s practice involves diseases of the ocular surface including dry eyes, allergies, infection, the latest in corneal, refractive, and cataract surgery, and glaucoma. In addition, Dr. Schechter is an expert consultant for Gerson Lehrman regarding the business and technology of eye care and consults for several ophthalmic pharmaceutical companies. He is also on the editorial board for Advanced Ocular Care, a journal that reaches the top 10% of ophthalmologists and select optometrists. Dr. Schechter has reviewed articles for Cornea, the British Journal of Ophthalmology, and the Journal of the American Academy of Ophthalmology. He has lectured internationally and published on the subjects of treatment of ocular tumors, lens implants and dry eyes. Dr. Schechter has also written a textbook chapter on surgical techniques. Dr. Schechter is involved in clinical research and consults for several ophthalmic pharmaceutical companies.
The Board has determined that Dr. Schechter’s extensive medical knowledge and consulting work make him a suitable member of the Company’s Board of Directors.
Zorik Spektor, M.D., F.A.A.P. was appointed as an independent member of the Board in April 2015. Dr. Spektor is a fellowship trained Pediatric Otolaryngologist and Head and Neck Surgeon and has been the Director of The Center for Pediatric ENT – Head and Neck Surgery in Boynton Beach, Florida since 1995. In addition, he is a Voluntary Assistant Professor of Surgery at the Department of Otolaryngology, University of Miami Leonard M. Miller School of Medicine, and an Affiliate Clinical Assistant Professor of Biomedical Science at Florida Atlantic University in Boca Raton, Florida. Dr. Spektor received his Bachelor’s Degree from Cornell University, and his Medical Doctorate at Albany Medical College of Union University in Albany, New York. Following Dr. Spektor’s completion of his residency training in Otolaryngology – Head and Neck Surgery at the University of Connecticut, he completed his fellowship in Pediatric Otolaryngology – Head and Neck Surgery at LeBonheur Children’s Medical Center in Memphis, Tennessee. Dr. Spektor is board certified in Otolaryngology – Head and Neck Surgery. He is a Fellow of the American Academy of Otolaryngology – Head and Neck Surgery and American Academy of Pediatrics. He is also a member of the American Society of Pediatric Otolaryngology and Society for Ear, Nose & Throat Advances in Children.
Prior to establishing the Center for Pediatric ENT – Head and Neck Surgery in 1995, Dr. Spektor was on the faculty of the University of Connecticut Health Science Center, Hartford Hospital and Newington Children’s Hospital, now known as Connecticut Children’s Hospital. He has lectured and presented extensively in the field of pediatric otolaryngology, and has authored numerous peer-reviewed publications. Dr. Spektor has been a presenter as well as an invited speaker at local, national and international conferences. He continually conducts clinical research studies, which have produced significant advances in the field of otolaryngology and pediatric otolaryngology. During the past decade he has been selected as one of the nation’s top doctors by several independent rating agencies for many consecutive years. Dr. Spektor has served on advisory boards for several medical device and pharmaceutical companies and has been involved in significant advances in the field of otolaryngology and Pediatric Otolaryngology.
The Board has determined that Dr. Spektor’s extensive medical knowledge, research experience and broad industry exposure make him a suitable member of the Company’s Board of Directors.
Mark R. Tobin, MBA, was appointed as an independent member of the Board in April 2015. Mark Tobin is currently the Senior Director, Corporate Strategy at Printronix, LLC, a leading manufacturer of industrial printers. From 2013 to 2017, Mr. Tobin served in various roles of increasing responsibility with NanoFlex Power Corporation, a publicly-listed advanced solar technology company, culminating as Executive Vice President and Chief Financial Officer. From 2013 to 2015, Mr. Tobin served as a Managing Director at Digital Offering, a merchant bank. Previously, from 2005 to 2013, he served as Director of Research and as a Senior Research Analyst at Roth Capital Partners, a leading boutique investment bank, where he oversaw equity research on hundreds of small-cap public companies across a variety of sectors. Prior to that, he was a Program Manager and Senior Systems Engineer at Science Applications International Corporation, a FORTUNE 500® scientific, engineering, and technology applications company. Mr. Tobin began his career as an officer in the United States Air Force, overseeing advanced technology development programs and representing the U.S. as a NATO delegate, and ultimately achieving the rank of Major. He graduated with honors from the U.S. Air Force Academy with a Bachelor’s of Science in Management and received an MBA from the University of Pittsburgh.
Perhaps he should have explained the situation to all shareholders via his blog rather than sh's reading it from an anonymous ihub poster.
SOON!!! ????
It's time he be more specific.
"Soon", "shortly", "coming weeks". Maybe he means "by end of february"?
"Uber and AirBnB can't be used as good examples."
I've never used either, but know of siblings. relatives, and friends who have used both. Getting to and fro Boston and avoiding the astronomical parking costs, or to Europe and finding reasonable priced shelter for a family of 5. My son played aau basketball, we had to shell out nearly $300/night for two bed hotels at many locations in the NE. Same with our daughters, who played competitive basketball/softball. Arrangements all made by the athletic orginizations.
As I commented recently to Plenty Paranoid, in business, budget and schedule are paramount. When costs sore without increased quality, look out below.
Management of affairs is essential in any endeavor.
Mayor Marty(Martin) Walsh speaks once a month on two Boston radio stations (89.7 fm, and 1030am) and has addressed these issues, as well as Gov Charlie Baker(both good men, imho(one democrat, one republican)).
Karin,
"Regarding compassionate use... the company doesn't have the funds to give it out. The fastest way to get it out to those in need is via ph4."
They have not the funds for ph4(less a deal is struck quickly). There has to be a fater way. I was in a clinical trial in the 80's/early 90's. Drug never marketed. After second life threating reaction, my PCP put me on an approved drug. Patient input is vital, and should be shared. Ibelieve drug companies involved with mytomorrows are compensated for the cost of drugs-better than nothing(will double check).
"Two-sided market places such as Uber and AirBnB have used technology to improve asset allocation through distributed supply and users have seen service levels rise dramatically and prices plummet. Could we apply the same logic to medications? That’s exactly what we’re trying to do at myTomorrows. We make treatments still in development available and, where the regulatory criteria are met, leave physicians and their patients to decide whether to start treatment based on the data. In the long term, this model could lead to lower drug costs. This is what we believe in?—?earlier access to new treatments which could help patients, at a lower cost to society."
Quote from the last paragraph of below link.
https://mytomorrows.com/en/blog-preview/can-the-price-of-drugs-be-justified-based-on-r-d-investment/
"But, you can't be implying that Leo did not anticipate salary and bonus costs."
I can't speak for him(and lately, he's not speaking for himself). Appears to me he anticipated the costs but mismanaged the schedule.
Where I come from, not finishing on time(schedule) can result in liquidated damages of 5k, 10k, or 20k, or more per day, depending on the client.
Budget and schedule are combed over monthly, at least, and reviewed with all supervisors and company execs.
PP,
Nice summary. I'm not sure what the current head count is, the ceo/cfo has not responded since early May. I suspect there are at least four there, they being the ceo/cfo($1,276.30/calendar day(cd), KM($638.15/cd), AB($1712.79/cd, and JH($605/cd) based on the 2017 10k and the feb 2018 10q denoting KM's 50% pay reduction. Those 4 salaries total $4232.24/cd (which include bonuses of $176000 for AB and 76313 for JH), assuming no change from 2017, or $380,901/q(29.3% of the $1.3M raised in 2018 Q1) Never mind any other costs.
Karin,
Clear as a bell(your response).
TY
KarinCA,
I invision the sachets as a "hard candy" more than a liquid source. My understanding of OM is that not one case is the same as far as location s in the mouth(I think my mother had it the late 1980's, though the term OM was never used, she defintely had painful mouth sores after chemo t-ments and her meals were most often soup form, apple sauce-nothing solid). I would think the rinse and spit would touch most, if not all, of the inflamed areas of the mouth. Is ipix working on the sachet on the premise that the sachet will disolve in the mouth into liquid form and then the patient swishes and spits? Or does the patient swallow the sachet and it's absorbed into the body which targets the OM?
My wish is the fda considers the ph2b B-OM results worthy of compassionate use(it is life threating at stage 4). There's a company in Europe called myTomorrows, started by a doctor whose father passed from lung cancer. There are American companies who are participating. Link below.
https://mytomorrows.com/en/team/#the-team
KarinCA,
I hope you're right. I'm only questioning why the need to change if it's working so well? Get what's working to the finish line and, at the same time, pursue possible better formulations(if they can afford it) rather than lose more time(which they can't afford).
Perhaps they are getting close to a partnership deal, who knows. You'd think they could provide an update on the cda interest. Now more than 20, less than 20, at least one or two?
I agree with you about B, but frustratingly admit that I have not ruled out P(not because of nerby's post https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135024214, nor George's incessant(won't bother with an example-one need not look far), but the company's own statement after the ph 2a in the 5/24/16 pr stating "
Included below is a sampling of responses that were authorized to be published:
“Well designed study, patients were pleased, minimal to no side effects."
“Good tolerability was shown with very few AEs reported. Good compliance and good patient satisfaction.”
“Overall impression of the study is very positive, as well as the patients’ satisfaction.”
When asked, “Why would you choose Prurisol (should it be approved) over another oral compound for psoriasis?” and “Why would you choose Prurisol over an injectable biologic?” responses included:
“Because [Prurisol] does not cause any severe side effects. Patients dislike needles and injections because they cause pain and discomfort."
“Patients overall prefer oral medications over injectable medication. Our experience with injectable studies for other indications has been that many subjects do not like taking them and those studies tend to be difficult compared to oral medications to recruit subjects.”
“Because of [Prurisol’s] low side effect profile.”
“Patients prefer oral treatments.”
http://www.ipharminc.com/press-release/2016/11/12/cellceutix-phase-2-trial-of-prurisol-for-mild-to-moderate-psoriasis-meets-primary-endpoint
By all company accounts ph2b for B-OM results are very good. Don't fix it if it ain't broke.
farrell90,
Not sure where you saw that. Last update dated 2/13/18 lists 34 sites.
(14) states with one study site each(Arizona,Geogia,Illinois,Indiana,Kansas,Kentucky,Missouri,Nevada,New Hampshire,New Jersey, New York,Oregon,Rhode Island,Virginia.
(4) states with two sites each- Arkansas,Colorado,Florida,Michigan
(1) state with 5 sites- California
(1) state with 7 sites- Texas
Total sites= 14+8+5+7= 34
https://www.clinicaltrials.gov/ct2/show/NCT02949388?term=innovation+pharmaceuticals&rank=3
frrol,
Thanks for the post. I brought up CPM(critical path scheduling(method) in the past). Doesn't sound as though he's familiar with it.
https://hbr.org/1963/09/the-abcs-of-the-critical-path-method
1. LE 6/15/18 response:We expect to update shareholders shortly. The anticipated sequence of news will be a) Data Lock, and b) thereafter, top-line results.
LE 1/16/18 pr:"... In coming weeks, we look forward to advancing these discussions with attractive partnership / licensing scenarios, towards determining the best path forward for the Company and its loyal shareholders.” Shortly?
2.LE 6/15/18: We sold stock at a fixed price. Albeit low but we needed funds for production of Brilacidin for further studies and other clinical trial payables. Hope the other payables do not include "the Ehrlich loan".
3.Please anticipate our update as all this is being worked on.
The anticipation.
frrol,
Let me know when you're available, I'll make every attempt to join you. TIAB, how bout you too? Ruininggirl welcome also.
1. Didn’t Leo and Menon fund the company for staters and I see nothing wrong in giving shares to the synagogue.
Answer: Yes they did in the pre-revenue days- at a self negogiated interest rate return.
2.i believe there would have been a deeper collapse in sp if they had made a share offering.
Answer- I believe the sp would not have tested these levels with better management.
3. The questions about management are often unsubstantiated nonsense and some directed at Leo are anti semetic.
Answer- For sure, SOME questions are unsubstatiated, but not all. You start your sentence with "The", the sole definite article in the english langauge, implying any questions regarding management are unsubstantiated. Regarding anti- semantics- you brought that up- one poster on this board stikes me as walking that line(and I refer to neither of us, but someone else).
"amen and great post. they 'gifted' themselves millions of free shares and refuse to show good faith and buy any shares on the open market with their own money.
but many continue to give them a free pass as the share price has collapsed and there is still no decent explanation for the .25 price aspire give away.
but lets continue to mock message board posters who have nothing to do with internal IPIX decisions and a .40 share price"
Direct the contents of your response to each paragraph that person stated.
Which paragraph is inaccurate?
1. LE and KM have never gifted themselves shares(never the synagouge way back when)?
2. They didn't give away shares recently at WELL below market share price?
3. Anyone who questions "management" is mocked by a few mb posters on this site?
George,
C'mon. Are you suggesting one should harbor no questions?
Your message has been for years, total "loyalty" of the company statements(best I can assess). What is your personnel loss to date (because, I suspect, you have not been playing the up's and down's. Have you?)?
Please share.
Some people have not a kar in the world.
Met with Dr Menon in late December, 2017. Nice guy. We talked for approximatley 1-1/2 hrs. Nary a phone call. Answered all my questions(Was told, by LE after my request for meeting, that he would not be around due to the holidays and the office would likely be short staffed).
Saw one other person in the office(coincidentally walked by while I was snapping a picture of the office, she's in it-I've seen that face before).
I requested the meeting because I was concerned about the sp decline.
I was told they where looking for p2b results perhaps by end of feb 2018, or there abouts.
And here we are.
58nout,
I'm not a fan of Bunny's arguments, but also can not, begrudgingly, ignore the fact that her(or his) forecasts have been more accurate than most. Unarguable in my view.
If what they(ipix) possess is so valuable, LE should take a pay cut from his exorbinant salary, and direct the differnce to a qualified, proven individual who has a history of success with the conditions they are focused on.
The more we languish, the more conviced I believe it's because of LE. Harness has grand credentials, Bertolino is also respected(best I can tell), Walters(if he's still there), top notch.
The only reason we are where we are(my thinking only) is the accountant from NY, and perhaps the speed stick guy(Menon-I jest). I met him, he seemed genuine.
Time is running short. I have my game plan locked in place, rough letters set to go to Massachusetts officials, if they(ipix) extend P2b yet again, this time into 3rd quarter(or beyond).
DuaberUP,
"....but I thought the CRO was in charge of the trial sites and data collection."
Yes, my understanding as well. Apologies.
p.s=I see I also screwed up the date of final patient visit-should read 12/21/17 not 12/21/18.
With 11 total outcome measures(2 primary, 9 secondary)per patient and each outcome measure being taken 9 times(baseline and every 2 wks) during 16 weeks(12 wks tment, 4 weeks followup) would yield 99 measurements per patient(11om/ptx9 pt visits). 99om/ptx 199pts=19701 total outcome measures(another way of saying it is 11om's/pt visitx199pts=2189om's/visit x 9visits=19701 total outcome measures.)
The final om's are taken and noted at the week 16 final visit and those 19701 om's(probably one piece of paper per patient in table format listing 11 rows of outcome measures and 1 column for each visit(9 total). I would think a trend in any one direction would stand right out by just reading across an outcome measures row and compare to baseline, much like a report one gets from their doctor after an annual visit where the patient can see clearly the change from previous measurements.
It's been about 176 days(5 mos. and 25 days) since 12/21/18. Take out 12 days for the end of december and new years, back out 23 weekends(46 days) and the 3 holidays after new years=115 workin daysx8 man hours/working day=920 hrs if one person is working on the analysis(the outcome measures appear pretty standard for a psoriasis trial).
Regarding your quote "....I believe we have a huge winner and thanks for the CRO having issues with collecting and posting the data in a timely fashion, I am getting discounted shares." I thought the data was collected at the 34 sites for the cro to analyze. Maybe ipix has not paid some of the sites as agreed and therefore some data has not been handed over to the cro? Who knows, the company is saying nothing.
Below are section copied and pasted from the CTI site, including a full description of the 11 primary outcome measures:
A subject studied under this clinical protocol will commence with a screening period of up to 4 weeks, a treatment period of 12 weeks, and a follow-up period of 4 weeks ending with an End of Study evaluation.
During treatment, subjects will return to the study center every 2 weeks. Efficacy assessments, including physician and patient rated endpoints, will be measured throughout the study. Safety and tolerability will be assessed by ascertainment of AEs and results of clinical laboratory testing, vital signs assessments, and need for concomitant medications.
At a subset of sites, blood samples for determination of plasma concentrations of Prurisol (abacavir glycolate) and abacavir, it's metabolite, will be obtained from subjects who consent to provide these samples. At selected sites, for those subjects consenting to photography, standardized digital photographs will be obtained for illustrative purposes.
Primary out come measures
1.Proportion of participants achieving at least a 75% reduction from baseline in PASI score (PASI75) at Week 12 [ Time Frame: 12 Weeks ]
The Psoriasis Area and Severity Index (PASI) quantifies the severity of psoriasis based on lesion severity and the percent of body surface area affected. It is a composite assessment, across body regions, reflected in a single score: 0 (no disease) to 72 (maximal disease).
2.Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 16 Weeks ]
Reporting of Adverse Events measurements, and reporting of adverse events.
Secondary Outcome Measures :
1.Proportion of subjects achieving a static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline [ Time Frame: 16 Weeks ]
The static Physician Global Assessment reflects an overall severity of the erythema, induration and scaling across all psoriatic lesions on a 5-point scale, where 0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe.
2.PASI75 response at time points through Week 16 [ Time Frame: 16 Weeks ]
The Psoriasis Area and Severity Index (PASI) quantifies the severity of psoriasis based on lesion severity and the percent of body surface area affected. It is a composite assessment, across body regions, reflected in a single score: 0 (no disease) to 72 (maximal disease).
3.The actual and change from baseline in patient-reported itch severity score [ Time Frame: 16 weeks ]
The severity of itching due to psoriasis will be assessed on a horizontal numeric rating scale, anchored by the terms "No itching" (0) and "Worst possible itching" (10).
4.Assessment of patient-reported quality of life by the Dermatology Life Quality Index (DLQI) [ Time Frame: 16 Weeks ]
The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology questionnaire that assesses patient health-related quality of life in adult subjects with skin diseases such as psoriasis
5,Assessment of patient-reported quality of life by the Short Form-36 Health Survey (version 2, acute form) [ Time Frame: 12 Weeks ]
The SF-36 is a widely used general health status questionnaire that assesses 8 domains of functional health and well-being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions
6.Assessment of patient-reported quality of life by the Euro-Qol 5 Dimensions Health State Profile [ Time Frame: 12 Weeks ]
The EQ-5D is a generic instrument designed to assess a subject's general health status. The instrument consists of a questionnaire and a visual analog scale (VAS)
7.Assessment of Patient Satisfaction with Study Treatment (PSST) [ Time Frame: 12 Weeks ]
Overall patient satisfaction with study treatment will be assessed on a 7-point rating scale, with response options range from "very dissatisfied" to "very satisfied"
8.Plasma concentrations of Prurisol [ Time Frame: 4 Weeks ]
Measurement of Prurisol (abacavir glycolate) from a subset of subjects in the trial
9.Plasma concentrations of abacavir [ Time Frame: Timeframe: 4 weeks ]
Measurement of abacavir, a metabolite of Prurisol, from a subset of subjects in the trial
Let's rate Leo,
1 highest rating, 5 lowest. Whole numbers only.
I'll give him a 4 because management of the schedule(it's cost me, based on his own words)
Rating log:
1 who date rated cumulative ratings
2 who date rated
3 who date rated
4 who date rated
kfc 6/13/18 4
5 who date rated
"I've seen this before on Penny Sleds: when finally Key Suppressed details emerge, and the reality hits, a Former Bull "take the arrows in the chest ' type for the CEO, ends up being the the Lead Plaintiff in the Class Action."
Bunny, believe me, I'm not happy with the sp, which is why I've become more vocal(post more often), but I know what I've read via company pr's/blogs/respected scientific advisors, HIGHLY RESPECTED JUDGES AND LAWYERS, and respected publications(not talking about seekingalpha or mako(for clarification).
I search for proof and justification of whatever I read if I can not verify myself. So, where have you "seen this before on Penny Sleds: when finally Key Suppressed details emerge, and the reality hits, a Former Bull "take the arrows in the chest ' type for the CEO, ends up being the the Lead Plaintiff in the Class Action."
Name the specific examples that fooled you.
thx
LR,
Good questions.
"If ALL of today's trades were executed in some kind of shady, sophisticated fashion by MMs do you think that those responsible for managing those trades would be happy with the maximum return to be divided between them all of $1,531.35? Is the atmosphere in which such lucrative returns are generated as high energy and competitive as that return would seem to imply? Folks seem to be contemplating some pretty deep thinkin' and fancy technology to get a piece of that $1,531.35."
Ya gotta believe Aspire was dumping some of those quarter grabs for a couple free carousel pony rides while sticking the rest in their pockets(.42/.25 yields a 68% return, not bad).
That info came from ihub post #120460 on 8/28/15. It's about half down the post.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=116588868
in response to:
Prurisol compared with approved Psoriasis drug Methotrexate
Methotrexate
63% reduction in lesion appearance
48% reduction in serum PRINS
46% reduction in serum IL-20
Lesions reoccurred in 61 days
Prurisol:
84% reduction in lesion appearance
96% reduction in serum PRINS
87% reduction in serum IL-20
No reoccurence of lesions within 180 days
Any one worth one's salt evaluates their estimates vs actual costs, by numerous line items, each broken down by equipment, labor,materials, fringe benefits, and other miscellaneous (small) expenditures, AND THEN AN EVAILUATION OF PRIOR STATEMENTS/PROJECTIONS FOLLOWS-MONTHLY(at the minimum). This must happen on a montly basis, to survive, and the resultant assessment conveyed to all(Owner, client, investors, and, most importantantly, the outcome measures shared with the workforce who compiles the data). Lest, one likely flounders. With out input, your left with nothing.
Checks and balances.
DaubersUP,
Agree with everything you stated. As noted in an earlier post of mine today, LE has not hesitated to contact the media in the past(https://www.bizjournals.com/boston/blog/bioflash/2015/08/my-visit-to-cellceutix-the-biotech-that-a-short.html) as noted by Don Seiffert in his BBJ 8/16/15 article.
I find it curious LE has not promoted the more recent successes through the local(Boston) media(Boston Business Journal, or Boston Globe, or Boston Herald, etc). It would likely shore up and raise the share price whiile making the Aspire transactions less dilutive to shareholders. Who knows, maybe he has called. Jounalists always like to be the first to announce a good scoop.
What I wrote is not inacurate at all, other than the $8900 per week ceo salary. You are correct, it is actually $8,958.65 ($465,850 annual salary per last 10K divided by 52 weeks=$8,958.65)
All else is truthful. The company contacted the Boston Business Journal and invited Don Seiffert to Beverly after one of the MAKO hit pieces and published an article in The BBJ on 8/16/15. An excerpt from that arrticle:
"Ehrlich — who calls the entire blog post a “lie” and a “fraud” — contacted me after I wrote a short blog on the matter earlier this week. He invited me to come out to Beverly to see the company first-hand, and I took him up on the offer. I had spoken to Ehrlich by phone a few times over the past two years but had never met him in person."
Seems Mr. Seiffert had spoken to LE "a few times over the past two years" prior to his 8/2015 visit
The article:
https://www.bizjournals.com/boston/blog/bioflash/2015/08/my-visit-to-cellceutix-the-biotech-that-a-short.html
I've contacted the BBJ keeping them up to with the company's progress via attaching the company pr's (started in early February 2018 attaching ipix 1/29/pr and some other pr's since. No response.
Here's the email first I sent to BBJ:
Hi Mr. Seiffert,
A few years back you did a story on a company based in Beverly, MA named Cellceutix(name changed last year to Innovation Pharmaceutical) (https://www.bizjournals.com/boston/ blog/bioflash/2015/08/my-visit-to-cellceutix-the-biotech-that-a-short.html).
Though their share price never recovered, their trials have succeeded with final phase 2b results for their drugs, Prurisol, to treat moderate to severe psoriasis, and Brilacidin, to treat oral mucositis , both due out any time this quarter..
Here is their most recent pr(1/29/18).
http://www.ipharminc.com/press-release/2018/1/29/innovation-pharmaceuticals-brilacidin-franchise-anchored-in-three-clinical-indications-oral-mucositis-inflammatory-bowel-disease-and-serious-skin-infections-expands-into-dermatologic-diseases
Any chance you could do a follow- up story?
Thanks,
xxx xxxxx
As ceo, cfo, receptionist, and investor contact(pr guy) he's juggling too much in my ipinion. He could easily, I would think, cut his own salary by $1000 per week and hire an office manager like a majority of similiar. I've also suggested he contact BBJ again, as well as the Boston Globe or Herald.
"Does anyone here really think Leo gives a rats a** whether the share price is .40, .45, .50, or .60 when a whole new ballgame is being negotiated (most likely) at the current time?"
He's proving he cares not what the sp is at, ever, as long as he begets his ~$8900 per week salary. He hasn't contacted the Boston Business Journal(Dan Seiffert) to promote the stellar results(which Seiffert has been made aware of many times-no follow-up by DS of BBJ) of the recent trial results like he did when under "mako"attack. No recent(past 6 months) from Sonis(the chipy bird for OM) or Farraye proclaiming B's stellar results- just an occassional blog(which doesn't reach the general public- only rhose who get on their website) or company pr which seems to always tank the sp after they mention they're going to reformulate the drug under study even though they proclaim phase 2 results with the original drugs are incredible (ex. B-OM after ph 2b puts them at the head of herd, but we are going to switch from rise ansd spit to sachets).
Soon, though....and I hope the guy who stated we are heading for a stone cold finish is dead wrong. Ask Lebron James and the Cav's about stone cold finishes.
He's the ceo, cfo, promo guy, janitor, etc
"Leo is playing the right game this time and my money is 100% behind him"
Are you implying Leo has played games previously that weren't right(eous)?
"I don't see any negatives to the company from missing the Q2 expected release of interim data from the P2B trial. I don't think any longs are going to be selling and certainly no institutional selling since we basically have no institutional holdings(IH)."
If the bus driver blows through another bus stop(Q2, 2018) with out a word, or another meek excuse without advising us when the bus will stop, I'm sure someone will advise authorities that this bus has been hijacked or the driver is possibly experiencing a hypoglycemic reaction.
Regarding your belief there will be no institutional selling- I agree- other than the sole IH which holds~ 300 shares, who could sell.
KarinCA,
Thank you, that's what I suspected but wasn't sure as they are on record stating staffing would be reduced.
All accomplished from 1960 to summer of 1969. Talk about good execution.
The rocket scientists at ipix appear to have completed stage 2 and await verification of whether those tests are successful. It's just taking a little longer as they've upgraded communication means a few times. The first upgrade consisted of an economical plan utilizing tin cans and kite string. Company officers quickly realised they were conned after shelling out some "heavy coin" for the string and cans. They then relied on pigeons, but having lost a bit on the last communication venture, they came to an agreement with a homeless man in Beverly who had access to an abundant supply of "home grown" Beverly pigeons residing under the Beverly train trestle(rather than trained homing pigeons(saved a ton not having to build a pigeon coop)). Another oops. It's all been rectified as they now have cutting edge voice mail (can't afford a secretary evidently).
So to all those complaining that it is taking too long remember, Rome was'nt built in a day.
"This thing’s a Saturn V rocket on the launch pad with steam billowing all around it."
Saturn V rockets compare nothing to today's technologies.
What year was Saturn V launched(rhetorical question)?
"IPIX is a coiled spring....."
Old claim yet proven.
Hopefully, soon.
4/13/15: https://seekingalpha.com/instablog/21116141-ellaruth/3782806-is-kevetrin-being-tested-with-dbp-techniques-burning-bushes-from-i-hub
7/16/14: https://seekingalpha.com/instablog/21116141-ellaruth/3069895-cellceutix-shares-are-undervalued-polymedix-assets-worth-50-times-book-value